Has inherent antimicrobial activity in vitro, and thereby can convert live pathogens into highly effective split vaccines

When used with intranasal vaccination, the NE adjuvant elicits both mucosal and systemic immunity. The technology is therefore uniquely suited to enable vaccines for both respiratory and sexually transmitted infections, which involve pathogens that enter the body across mucosal surfaces. The mucosal immunity elicited by NE vaccines provides protection against these infections at their port of entry, and has demonstrated the potential to reduce carriage of the associated pathogen.

How Do Intranasal NE Vaccines Work?

NE vaccines can be applied intranasally, using either a dropper or a sprayer device. As shown in the figure below, the vaccine droplets readily permeate the nasal tissue, which is rich in immune-presenting cells. Dendritic cells sample the vaccine at the nasal mucosa, and carry the antigen back to the immune system to elicit both a mucosal and a systemic response.2 Intranasal NE vaccines have been shown to be immunogenic, safe and well tolerated in Phase 1 clinical trials.

Studies Conducted to Date

BlueWillow Biologics has conducted numerous vaccine studies demonstrating the key attributes of the NE adjuvant, encompassing several diseases and animal models. A selection of studies completed to date is summarized below: